MX2021003636A - Receptor antigenico quimerico. - Google Patents

Receptor antigenico quimerico.

Info

Publication number
MX2021003636A
MX2021003636A MX2021003636A MX2021003636A MX2021003636A MX 2021003636 A MX2021003636 A MX 2021003636A MX 2021003636 A MX2021003636 A MX 2021003636A MX 2021003636 A MX2021003636 A MX 2021003636A MX 2021003636 A MX2021003636 A MX 2021003636A
Authority
MX
Mexico
Prior art keywords
antigen receptor
chimeric antigen
car
binds
disease
Prior art date
Application number
MX2021003636A
Other languages
English (en)
Inventor
Martin Pulé
Shaun Cordoba
Simon Thomas
Shimobi Onuoha
Lim Wen Chean
Biao Ma
Mathieu Ferrari
Original Assignee
Autolus Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1815775.0A external-priority patent/GB201815775D0/en
Priority claimed from GBGB1902021.3A external-priority patent/GB201902021D0/en
Application filed by Autolus Ltd filed Critical Autolus Ltd
Publication of MX2021003636A publication Critical patent/MX2021003636A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención provee un receptor antigénico quimérico (CAR) que se une a un antígeno objetivo en baja densidad, el cual comprende un dominio de unión a antígenos Fab. La invención también se refiere a células que expresan este CAR, y a su uso en el tratamiento de enfermedades.
MX2021003636A 2018-09-27 2019-09-26 Receptor antigenico quimerico. MX2021003636A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1815775.0A GB201815775D0 (en) 2018-09-27 2018-09-27 Chimeric antigen receptor
GBGB1902021.3A GB201902021D0 (en) 2019-02-14 2019-02-14 Chimeric antigen receptor
PCT/GB2019/052726 WO2020065330A2 (en) 2018-09-27 2019-09-26 Chimeric antigen receptor

Publications (1)

Publication Number Publication Date
MX2021003636A true MX2021003636A (es) 2021-07-21

Family

ID=68084861

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003636A MX2021003636A (es) 2018-09-27 2019-09-26 Receptor antigenico quimerico.

Country Status (13)

Country Link
US (2) US20220033509A1 (es)
EP (1) EP3856775A2 (es)
JP (2) JP7458382B2 (es)
KR (1) KR20210066865A (es)
CN (1) CN112771076B (es)
AU (1) AU2019348975A1 (es)
BR (1) BR112021004986A2 (es)
CA (1) CA3113896A1 (es)
CL (1) CL2021000736A1 (es)
IL (1) IL281428A (es)
MX (1) MX2021003636A (es)
SG (1) SG11202102781UA (es)
WO (1) WO2020065330A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201317928D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Molecule
AU2018311345A1 (en) * 2017-08-02 2020-02-27 Autolus Limited Cells expressing a chimeric antigen receptor or engineered TCR and comprising a nucleotide sequence which is selectively expressed
GB202005216D0 (en) 2020-04-08 2020-05-20 Autolus Ltd Cell
WO2024097992A2 (en) 2022-11-04 2024-05-10 Umoja Biopharma, Inc. Particles displaying adhesion-molecule fusions

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011516041A (ja) 2008-03-12 2011-05-26 イムクローン・リミテッド・ライアビリティ・カンパニー 抗ｔｙｒｐ１抗体
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
WO2015069922A2 (en) 2013-11-06 2015-05-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Alk antibodies, conjugates, and chimeric antigen receptors, and their use
DK3071222T3 (da) 2013-11-21 2020-11-16 Ucl Business Ltd Celle
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
MX2017001011A (es) * 2014-07-21 2018-05-28 Novartis Ag Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
US20170226216A1 (en) * 2014-07-24 2017-08-10 Bluebird Bio, Inc. Bcma chimeric antigen receptors
GB201415347D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
MX2017007249A (es) 2014-12-05 2018-01-25 Memorial Sloan Kettering Cancer Center Receptores de antigeno quimerico dirigidos al receptor fc 5 similar y sus usos.
EP3233900A2 (en) 2014-12-19 2017-10-25 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptors and methods of use thereof
JP6633081B2 (ja) 2014-12-24 2020-01-22 ユーシーエル ビジネス リミテッド 細胞
GB201501936D0 (en) 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
GB201503742D0 (en) 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
GB201504840D0 (en) 2015-03-23 2015-05-06 Ucl Business Plc Chimeric antigen receptor
BR112017019914A2 (pt) * 2015-04-13 2018-06-19 Pfizer receptores de antígenos quiméricos direcionados para antígeno de amadurecimento de células b
EP3298032A1 (en) * 2015-05-18 2018-03-28 Bluebird Bio, Inc. Anti-ror1 chimeric antigen receptors
JP2018522833A (ja) * 2015-06-12 2018-08-16 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． キメラ抗原受容体（ｃａｒ）コンストラクト、及びｃａｒコンストラクトを発現するｔ細胞（ｃａｒ−ｔ）またはｎｋ細胞（ｃａｒ−ｎｋ）による疾患治療
GB201514874D0 (en) * 2015-08-20 2015-10-07 Autolus Ltd Cell
GB201514875D0 (en) 2015-08-20 2015-10-07 Autolus Ltd Receptor
EP3368574A1 (en) 2015-10-30 2018-09-05 NBE-Therapeutics AG Anti-ror1 antibodies
WO2017156479A1 (en) * 2016-03-11 2017-09-14 Bluebird Bio, Inc. Ror1 chimeric antigen receptors
CN105777911B (zh) * 2016-04-12 2019-07-02 上海优卡迪生物医药科技有限公司 抗bcma嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用
GB201801831D0 (en) * 2018-02-05 2018-03-21 Autolus Ltd Chimeric receptor

Also Published As

Publication number Publication date
IL281428A (en) 2021-04-29
JP7458382B2 (ja) 2024-03-29
JP2022502036A (ja) 2022-01-11
JP2023169370A (ja) 2023-11-29
US20220033509A1 (en) 2022-02-03
SG11202102781UA (en) 2021-04-29
BR112021004986A2 (pt) 2021-06-08
EP3856775A2 (en) 2021-08-04
WO2020065330A3 (en) 2020-05-14
AU2019348975A1 (en) 2021-03-25
KR20210066865A (ko) 2021-06-07
CN112771076B (zh) 2024-04-02
CA3113896A1 (en) 2020-04-02
US20220356260A1 (en) 2022-11-10
WO2020065330A2 (en) 2020-04-02
CL2021000736A1 (es) 2021-08-20
CN112771076A (zh) 2021-05-07

Similar Documents

Publication Publication Date Title
MX2021003636A (es) Receptor antigenico quimerico.
PH12018501554A1 (en) Ror1 antibody compositions and related methods
MX2023001727A (es) Anticuerpos anti-c5 y usos de los mismos.
CY1124771T1 (el) Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων
JOP20210076A1 (ar) تركيبات أجسام مضادة ثنائية الاختصاص لربط خلايا تائية
PH12018500295A1 (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
PH12019502275A1 (en) Anti-ilt4 antibodies and antigen-binding fragments
PH12018500156A1 (en) Antibody constructs for egfrviii and cd3
PH12016502064A1 (en) Human antibodies to middle east respiratory syndrome-coronavirus spike protein
EA201891066A1 (ru) Антитела к ror1
MX2020003046A (es) Anticuerpos anti-hla-a2 y metodos para utilizar los mismos.
EP3593812A3 (en) Treatment of cancer using chimeric antigen receptor
MX2016011155A (es) Anticuerpo que une erbb-2 y erbb-3.
MX2019015352A (es) Linfocitos t con receptor de antigeno quimerico (car) para receptor 1 huerfano tipo receptor de tirosina cinasa (ror 1).
MX2017013348A (es) Construcciones de anticuerpos biespecificos contra cdh3 y cd3.
WO2016205551A3 (en) Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
WO2021048564A3 (en) Antigen-binding domain
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
AU2018338423A1 (en) Novel anti-HLA-A2 antibodies and uses thereof
EA201992316A1 (ru) Композиции и способы для диагностики рака предстательной железы
MX2020010104A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado.
MX2022007855A (es) Anticuerpos hvem anti-humano (tnfrsf14) y usos de los mismos.
CR20220061A (es) Anticuerpos que se unen a células cancerosas y que dirigen radionucleidos a dichas células
MX2021003756A (es) Composiciones farmaceuticas que comprenden anticuerpos anti cumulo de diferenciacion 37 (cd37) biespecificos.
WO2019241721A3 (en) Compositions and methods relative to igm memory b cells